Reuters logo
BRIEF-Transgene announces first patient has been treated in TG6002 trial
October 26, 2017 / 4:43 PM / a month ago

BRIEF-Transgene announces first patient has been treated in TG6002 trial

Oct 26 (Reuters) - TRANSGENE SA:

* ‍FIRST PATIENT TREATED IN A PHASE 1/2A TRIAL (ONCOVIRAC) OF NOVEL ONCOLYTIC VIRUS TG6002 IN RECURRENT GLIOBLASTOMA​

* FIRST-IN-HUMAN TRIAL TO DELIVER FIRST READOUTS IN H2 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below